Johnson & Johnson (JNJ)
165.52
+0.88 (0.53%)
Upcoming Events
Latest Headlines
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
September 15, 2024 2:30 AM - PR NewsWire
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
September 14, 2024 9:45 AM - PR NewsWire
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
September 14, 2024 3:10 AM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Sep 10 Filed by: Woods Eugene A.
September 12, 2024 4:45 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Sep 10 Filed by: HEWSON MARILLYN A
September 12, 2024 4:44 PM - SEC Filing
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
September 11, 2024 6:22 PM - PR NewsWire
Johnson & Johnson (JNJ) reports dexamethasone reduced infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT
September 10, 2024 5:17 PM - StreetInsider
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
September 10, 2024 5:15 PM - PR NewsWire
Johnson & Johnson (JNJ) Announces Retirement of D. S. Davis from Board
September 10, 2024 4:28 PM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Sep 10
September 10, 2024 4:26 PM - SEC Filing
Johnson & Johnson (JNJ) Reports RYBREVANT plus LAZCLUZE Showed strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
September 9, 2024 6:12 AM - StreetInsider
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
September 8, 2024 1:47 PM - PR NewsWire
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
September 5, 2024 4:30 PM - BizWire
Zimmer Biomet stock falls on warning
September 5, 2024 10:52 AM - StreetInsider
Johnson & Johnson adds $1.1 billion to proposed talc settlement
September 4, 2024 4:12 PM - StreetInsider
J&J (JNJ) Raises Settlement Offer by About $1 Billion to Roughly $9 Billion - WSJ
September 4, 2024 3:59 PM - StreetInsider
Judge rules J&J owes Auris investors $1 billion related to 2019 robotics deal
September 4, 2024 11:00 AM - StreetInsider
Form 4 JOHNSON & JOHNSON For: Aug 30 Filed by: Decker Robert J
September 3, 2024 4:48 PM - SEC Filing
Form 144 JOHNSON & JOHNSON Filed by: Decker Robert J
August 30, 2024 3:51 PM - SEC Filing
Form N-PX JOHNSON & JOHNSON For: Jun 30
August 29, 2024 2:06 PM - SEC Filing
Johnson & Johnson (JNJ) seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
August 29, 2024 8:00 AM - StreetInsider
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
August 29, 2024 8:00 AM - PR NewsWire
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
August 27, 2024 8:00 AM - PR NewsWire
Form 8-K JOHNSON & JOHNSON For: Aug 26
August 26, 2024 4:26 PM - SEC Filing
Johnson & Johnson's (JNJ) EVP, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
August 26, 2024 8:06 AM - StreetInsider
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
August 26, 2024 8:00 AM - BizWire
Johnson & Johnson (JNJ) To End Some Up-Front Discounts For Hospitals - WSJ
August 23, 2024 2:13 PM - StreetInsider
J&J in talks with holdouts to $6.5 billion talc settlement
August 23, 2024 2:03 PM - StreetInsider
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ) after V-Wave deal
August 20, 2024 12:37 PM - StreetInsider
Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn
August 20, 2024 8:40 AM - StreetInsider
Johnson & Johnson gets green light for lung cancer combination treatment
August 20, 2024 7:49 AM - StreetInsider
J&J to buy medical device maker V-Wave for up to $1.7 billion
August 20, 2024 7:45 AM - StreetInsider
Johnson & Johnson (JNJ) to Acquire V-Wave
August 20, 2024 7:30 AM - StreetInsider
Johnson & Johnson to Acquire V-Wave
August 20, 2024 7:30 AM - BizWire
J&J's chemotherapy-free treatment for lung cancer gets US approval
August 20, 2024 7:17 AM - StreetInsider
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE approved in the U.S.
August 20, 2024 7:01 AM - StreetInsider
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
August 20, 2024 7:00 AM - PR NewsWire
South Carolina Jury Awards $63.4 Million to Johnson & Johnson Asbestos Victim
August 15, 2024 7:08 PM - BizWire
Johnson & Johnson (JNJ) Preparing to Have Subsidiary Seek Bankruptcy Protection to Consummate Talc Settlement as Soon as Next Week - Reuters
August 14, 2024 12:24 PM - StreetInsider
Johnson & Johnson (JNJ) spreader active in August 155 and August 23 weekly 155 puts
August 14, 2024 10:50 AM - StreetInsider
Lawyers for Ovarian Cancer Victims Endorse Proposed Texas Two-Step Remedy
August 13, 2024 9:00 AM - BizWire
J&J wins plaintiff support for $6.5 billion baby powder settlement - Bloomberg
August 13, 2024 4:12 AM - StreetInsider
J&J has enough support from claimants for $6.5-billion talc settlement, Bloomberg reports
August 12, 2024 3:17 PM - StreetInsider
Johnson & Johnson (JNJ) Gets Plaintiff Backing For $6.5 Billion Baby Powder Accord - Bloomberg
August 12, 2024 2:44 PM - StreetInsider
Form 13F-HR JOHNSON & JOHNSON For: Jun 30
August 9, 2024 4:36 PM - SEC Filing
Johnson & Johnson (JNJ) option implied volatility flat into a talc settlement draws near
August 9, 2024 3:29 AM - StreetInsider
Upside seen for Johnson & Johnson ahead of talc vote outcome
August 8, 2024 4:00 PM - StreetInsider
Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
August 7, 2024 5:00 PM - PR NewsWire
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 6, 2024 9:00 AM - StreetInsider
DePuy Synthes Launches its First Active Spine Robotics and Navigation Platform
August 2, 2024 8:02 AM - PR NewsWire
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
July 30, 2024 6:42 PM - PR NewsWire
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
July 29, 2024 4:00 PM - BizWire
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
July 26, 2024 9:38 AM - BizWire
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
July 26, 2024 9:05 AM - BizWire
Form 10-Q JOHNSON & JOHNSON For: Jun 30
July 25, 2024 4:03 PM - SEC Filing
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
July 23, 2024 4:00 PM - BizWire
Daiwa Securities Downgrades Johnson & Johnson (JNJ) to Neutral (3)
July 23, 2024 3:35 AM - StreetInsider
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
July 22, 2024 11:59 AM - BizWire
Johnson & Johnson (JNJ) seeks U.S. FDA approval of SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression
July 22, 2024 8:00 AM - StreetInsider
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
July 22, 2024 8:00 AM - PR NewsWire
Johnson & Johnson (JNJ) PT Lowered to $185 at TD Cowen
July 18, 2024 9:17 AM - StreetInsider
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
July 18, 2024 6:14 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $169 at Morgan Stanley
July 18, 2024 12:29 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $160 at Stifel
July 17, 2024 1:58 PM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Jul 17
July 17, 2024 8:15 AM - SEC Filing
Midday movers: Nvidia, TSMC, Five Below, Spirit Airlines and Eli Lilly fall
July 17, 2024 7:48 AM - StreetInsider
Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates
July 17, 2024 6:39 AM - StreetInsider
Johnson & Johnson (JNJ) Declares $1.24 Quarterly Dividend; 3.3% Yield
July 17, 2024 6:25 AM - StreetInsider
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
July 17, 2024 6:25 AM - BizWire
J&J beats Wall St estimates on strong drug sales ahead of Stelara competition
July 17, 2024 6:22 AM - StreetInsider
Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
July 17, 2024 6:21 AM - StreetInsider
Johnson & Johnson reports Q2 2024 results
July 17, 2024 6:20 AM - BizWire
Stocks expected to have increasing option volume: JNJ ELV USB SYF CFG ALLY BE SAVE JBHT
July 17, 2024 6:00 AM - StreetInsider
Tech weakness, Taiwan concerns, Amazon's Prime Day - what's moving markets
July 17, 2024 5:47 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 5.5 calls to 1 put with focus on July and August 155 calls into quarter results
July 16, 2024 11:04 AM - StreetInsider
Johnson & Johnson (JNJ) July 149 straddle into quarter results
July 16, 2024 5:19 AM - StreetInsider
JNJ Q2 earnings preview: This is what analysts expect
July 16, 2024 4:00 AM - StreetInsider
Dow Jones, Nasdaq, S&P 500 weekly preview: Focus shifts to Q2 earnings
July 15, 2024 8:23 AM - StreetInsider
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
July 15, 2024 8:05 AM - Globe NewsWire
Legend Biotech said to have received takeover approach, hired Centerview - source
July 12, 2024 1:45 PM - StreetInsider
Johnson & Johnson (JNJ) Announces Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
July 11, 2024 7:30 AM - StreetInsider
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
July 11, 2024 7:30 AM - BizWire
Form 4 JOHNSON & JOHNSON For: Jul 08 Filed by: Broadhurst Vanessa
July 9, 2024 5:49 PM - SEC Filing
Emergent BioSolutions (EBS), Johnson & Johnson (JNJ) Settle Claims Over Vaccine Manufacturing Pact - Bloomberg
July 8, 2024 5:01 PM - StreetInsider
Johnson & Johnson (JNJ) option IV flat into 2024 elections
July 3, 2024 4:55 AM - StreetInsider
Here are high-quality stock names that pay dividends
July 2, 2024 11:00 PM - StreetInsider
Johnson & Johnson (JNJ) Reports CARVYKTI achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
July 2, 2024 7:30 AM - StreetInsider
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
July 2, 2024 7:30 AM - PR NewsWire
Johnson & Johnson (JNJ) reports positive results from the nipocalimab Phase 3 Vivacity-MG3 study
June 28, 2024 11:30 AM - StreetInsider
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
June 28, 2024 11:30 AM - PR NewsWire
CHMP issues positive opinion for J&J's (JNJ) BALVERSA for unresectable or metastatic urothelial carcinoma
June 28, 2024 11:08 AM - StreetInsider
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
June 27, 2024 6:46 PM - BizWire
Form 11-K/A JOHNSON & JOHNSON For: Dec 31
June 25, 2024 4:19 PM - SEC Filing
Form 11-K JOHNSON & JOHNSON For: Dec 31
June 24, 2024 4:44 PM - SEC Filing
Form 11-K JOHNSON & JOHNSON For: Dec 31
June 24, 2024 4:43 PM - SEC Filing
Johnson & Johnson (JNJ) Completes Acquisition of Proteologix
June 21, 2024 7:30 AM - StreetInsider
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
June 21, 2024 7:30 AM - BizWire
Johnson & Johnson (JNJ) Seeking FDA Approval of TREMFYA for Active Crohn's disease
June 20, 2024 4:31 PM - StreetInsider
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
June 20, 2024 4:30 PM - PR NewsWire
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
June 20, 2024 8:00 AM - PR NewsWire
Stifel Comments on Johnson & Johnson (JNJ) Post EU Robotic Tour: 'JNJ’s laparoscopic surgery business continues to be on the losing end of robotic share gain'
June 18, 2024 9:38 AM - StreetInsider
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
June 17, 2024 5:55 PM - BizWire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 9:00 AM - StreetInsider
Johnson & Johnson (JNJ): Subcutaneous amivantamab BLA submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
June 17, 2024 8:02 AM - StreetInsider
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
June 17, 2024 8:00 AM - PR NewsWire
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
June 17, 2024 6:23 AM - StreetInsider
Full Article List
